EGFR and neoplasm: While reducing immunosuppression through immune targeting and strengthening ICD, this combination also suppressed tumor proliferation by inhibiting tyrosine kinases (including EGFR signaling and RTK signaling) and effectively reduced drug resistance during the treatment process.